Regulatory filings are targeted for late 2026, aiming for commercial availability in 2027, supported by accelerated or conditional pathways.
OS Therapies received USD 3.15 million in UK VAT refunds; a further USD 7.2 million in VAT and R&D tax credits remains pending to fund a Phase 3 start.
Interim Phase 2b survival findings
OS Therapies reported interim 3-year survival findings from its Phase 2b OST-HER2 trial in fully resected pulmonary metastatic osteosarcoma.
Results have been presented in this interim analysis; final data analysis is expected within about a month.
Patients given OST-HER2 showed better long-term survival than a published historical comparison group, supporting the case for earlier market access.
OSTX•
